Gastrointestinal stromal tumours: three perspectives on current diagnosis and therapy

Miettinen, 2001, Gastrointestinal stromal tumors - definition, clinical, histological, immunchistochemical, and molecular genetic features and differential diagnosis, Virchows Archiv, 438, 1, 10.1007/s004280000338 DeMatteo, 2002, Clinical management of gastrointestinal stromal tumors: before and after STI571, Hum Pathol, 33, 466, 10.1053/hupa.2002.124122 Kindblom, 1998, Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal, Am J Pathol, 152, 1259 Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577 Buchdunger, 2000, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J Pharmacol Exp Ther, 295, 139 Buchdunger, 1996, Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative, Cancer Res, 56, 100 Heinrich, 2002, Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT positive malignancies, J Clin Oncol, 20, 1692, 10.1200/JCO.20.6.1692 Okuda, 2001, ARG tyrosine kinase activity is inhibited by STI571, Blood, 97, 2440, 10.1182/blood.V97.8.2440 Dewar, 2005, Macrophage colony stimulating factor receptor, c-fins, is a novel target of imadnib, Blood, 105, 3127, 10.1182/blood-2004-10-3967 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 van Oosterom, 2002, Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 38, S83, 10.1016/S0959-8049(02)80608-6 van Oosterom, 2001, Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7 Verweij, 2003, Eur J Cancer, 39, 2006, 10.1016/S0959-8049(02)00836-5 Zalcberg, 2005, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg, Eur J Cancer, 41, 1751, 10.1016/j.ejca.2005.04.034 Demetri, 2004, NCCN Task Force Report: optimal management of patients with gastrointestinal stromal tumor (GIST) - expansion andupdate of NCCN Clinical Practice Guidelines, S1 Blay, 2005, Consensus meeting for the management of gastrointestinal stromal tumors, 16, 566 Benjamin, 2003, We should decist using RECIST, at least in GIST Joensuu, 2001, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor, N Engl J Med, 344, 1052, 10.1056/NEJM200104053441404 Verweij, 2004, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, Lancet, 364, 1127, 10.1016/S0140-6736(04)17098-0 Blanke, 2006, Outcome of advanced GIST patients treated with imadnib mesylate, 4, 88 Heinrich, 2002, KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs), 21, 2a Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190 Debiec-Rychter, 2004, Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 40, 689, 10.1016/j.ejca.2003.11.025 Heinrich, 2003, PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 299, 708, 10.1126/science.1079666 Corless, 2005, PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib, J Clin Oncol, 23, 5357, 10.1200/JCO.2005.14.068 Blackstein, 2005, Clinical benefit of imatinib in patients with metastatic gastrointestinal stromal tumors negative for the expression of CD117 in the 50033 trial, 818s Rankin, 2004, Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study 50033, 23, 815 Blay, 2004, Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group, 23, 815 Le Cesne, 2005, Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life, 823s